Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mifeprex patent extension

Executive Summary

Danco Labs expects Mifeprex (mifepristone, RU-486) to receive a two-year patent extension as a result of FDA's reassessment of the regulatory review period for the abortion drug, in lieu of the four-year extension originally expected. FDA said in an Oct. 24 Federal Register notice that it changed its determination of the start date for the Mifeprex IND from 1994 to the pre-Waxman/Hatch date of 1983 (1"The Pink Sheet" Oct. 28, p. 21). A two-year extension will give Mifeprex exclusivity through January 2004...
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS040735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel